<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2023.1270793</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Case report: Episodic psychosis caused by a novel <italic>SCP2</italic> splicing mutation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Tang</surname> <given-names>Haiyan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/2394720/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Luo</surname> <given-names>Yingying</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1874033/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Tang</surname> <given-names>Zhenchu</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/885498/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Tang</surname> <given-names>Jianguang</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Fang</surname> <given-names>Jia</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/276818/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>The Second Xiangya Hospital, and Center for Medical Genetics and Hunan Key Laboratory of Medical Genetics, Department of Medical Genetics, School of Life Sciences, Central South University, Changsha</institution>, <addr-line>Hunan</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Neurology, The Second Xiangya Hospital of Central South University</institution>, <addr-line>Changsha</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Muthukumar Karuppasamy, University of Alabama at Birmingham, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Jose Laffita Mesa, Karolinska Institutet (KI), Sweden; Abhishek Guha, University of Alabama at Birmingham, United States</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Jia Fang <email>507092&#x00040;csu.edu.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>10</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1270793</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>08</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>09</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2023 Tang, Luo, Tang, Tang and Fang.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Tang, Luo, Tang, Tang and Fang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license></permissions>
<abstract>
<p>SCPx deficiency is a rare disorder of peroxisomal beta-oxidation dysfunction, and it has only been documented in two patients thus far. In the previously reported patients, both patients were primarily presented with slowly progressive dystonia or ataxia, and they both displayed symmetrical lesions in the thalamus and brainstem on magnetic resonance imaging. This study presents the third patient exhibiting a similar neuroimaging abnormality but a notably different clinical phenotype characterized by episodic psychosis. Through whole-exome sequencing, we identified a homozygous splicing mutation in <italic>SCP2</italic> (c.674 &#x0002B; 1G &#x0003E; C), and further RNA sequencing revealed exon 8 skipping in the mature transcripts of <italic>SCP2</italic>. This study significantly expands our understanding of the genotypic and phenotypic spectrum associated with <italic>SCP2-</italic>related metabolic encephalopathy.</p></abstract>
<kwd-group>
<kwd>episodic psychosis</kwd>
<kwd>peroxisomal beta-oxidation</kwd>
<kwd>SCPx deficiency</kwd>
<kwd>SCP2 mutation</kwd>
<kwd>splicing mutation</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="5"/>
<page-count count="5"/>
<word-count count="2404"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Neurogenetics</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p><italic>SCP2</italic> gene is located on chromosome 1p32 and encodes two distinct proteins, sterol carrier protein X (SCPx) and sterol carrier protein 2 (SCP2), <italic>via</italic> separate promoters (<xref ref-type="bibr" rid="B1">1</xref>). SCPx functions as a peroxisomal enzyme with thiolase activity involved in peroxisomal beta-oxidation. Its primary role is in the degradation of very long-chain fatty acids (VLCFA) and branched-chain fatty acids such as phytanic and pristanic acid. In the current study, we reported the case of a patient who presented with episodic psychosis, which was determined to be caused by a novel <italic>SCP2</italic> splicing mutation.</p></sec>
<sec id="s2">
<title>Case description</title>
<p>Ethics approval was obtained from the Second Xiangya Hospital, Central South University (Changsha, China). Written informed consent was obtained from the patient and his family members for their enrollment. A 48-year-old male was admitted to our hospital thrice between 2012 and 2017 due to episodic psychosis. During each attack, he experienced delusions, irritability, aggressive behavior, bursts of uncontrollable laughter, crying, and talking to himself. Each episode was triggered by an acute upper respiratory tract infection. He was the third child of healthy, non-consanguineous parents with no family history of relevant conditions. The patient had experienced stuttering and tremors in his lips and hands for as long as his son could remember. Physical signs were the same during each episode. Examination revealed confusion, restlessness, and disorientation to time, person, and place, with normal limb muscle strength, brisk deep tendon reflexes, positive bilateral palmomental reflex, sucking reflex, and Babinski&#x00027;s reflex. On each occasion, cranial magnetic resonance imaging (MRI) revealed symmetrical T2 hyperintense signals in the thalamus, mesocephalon, and pons without gadolinium enhancement (see <xref ref-type="fig" rid="F1">Figure 1</xref>). The cerebrospinal fluid (CSF) showed no abnormalities. No antibodies were detected for autoimmune encephalitis, paraneoplastic neurological syndromes, and rheumatologic disorders. Ceruloplasmin, lactic acid, free carnitine, acylcarnitines, amino acids in the blood, and organic acids in the urine were all within normal ranges. Nerve conduction studies and needle electromyography showed no abnormalities. The patient was previously diagnosed with viral encephalitis, cerebral infarction, or mitochondrial encephalopathy. He received appropriate treatments, such as antiviral and antiplatelet therapy, during each hospitalization. Psychiatric symptoms gradually improved after 3&#x02013;6 months of treatment with antipsychotic drugs such as olanzapine or quetiapine. Between episodes, the patient was able to care for himself and engage in communication with others independently.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Cranial MRI of the patient. Axial T1 and T2-weighted imaging showed hypointense and hyperintense signals in the thalamus, mesocephalon, and pons (indicated in red arrow).</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fneur-14-1270793-g0001.tif"/>
</fig>
<p>In January 2018, the patient was readmitted to the hospital for continuous generalized tonic-clonic seizures (GTCS) that lasted 18 h without recovery between seizures. The GTCS occurred every 10 min, with each seizure lasting 1&#x02013;2 min. Upon admission, he presented with confusion. The physical examination was limited due to poor cooperation. Pristanic acid concentration was slightly elevated at 0.62 &#x003BC;mol/L, just above the control range (&#x0003C;0.60 &#x003BC;mol/L), while VLCFA and phytanic acid were within the standard limit. Cranial MRI revealed abnormalities consistent with prior findings.</p>
<p>Whole-exome sequencing of the proband revealed a homozygous splicing mutation, c.674 &#x0002B; 1G &#x0003E; C, in <italic>SCP2</italic> (NM_002979.5) in chr1:53442442 (hg19). Sanger sequencing confirmed the candidate mutation in the proband and his family members. The proband&#x00027;s father and sisters were heterozygotes at this position (see <xref ref-type="fig" rid="F2">Figures 2A</xref>, <xref ref-type="fig" rid="F2">B</xref>). RNA sequencing identified two outlier junctions in the <italic>SCP2</italic> cluster, providing support for the skipping of the eighth exon (<italic>p</italic> = 4.81E-12, FDR = 0, and <italic>p</italic> = 1.31E-4, FDR = 0.008) (see <xref ref-type="fig" rid="F2">Figures 2C</xref>, <xref ref-type="fig" rid="F2">D</xref>). At the mRNA level, cDNA analysis validated the aberrant splicing pattern between the sixth and ninth exons in the patient&#x00027;s sample through the agarose gel electrophoresis of reverse transcription polymerase chain reaction amplicons (RT-PCR) product (see <xref ref-type="fig" rid="F2">Figure 2E</xref>). Sanger sequencing of the RT-PCR product confirmed the exon 8 skipping event in the patient (see <xref ref-type="fig" rid="F2">Figure 2F</xref>). The eighth exon has a length of 87 base pairs. This mutation results in the loss of 29 amino acid residues in the patients&#x00027; SCPx protein. The allele frequency is approximately 0.00001992 in the gnomAD database. In the case of SCP2, loss of function is a recognized disease mechanism. The variant c.674 &#x0002B; 1G &#x0003E; C in <italic>SCP2</italic> was classified as &#x0201C;pathogenic&#x0201D; based on the ACMG guidelines.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p><bold>(A)</bold> Pedigree chart of this family. <bold>(B)</bold> Validation of <italic>SCP2</italic> c.674 &#x0002B; 1 G&#x0003E;C by Sanger sequence in the patient and his father. The ref indicates the reference sequence, with capital letters and lowercase, representing the nucleotide in the exon and intron regions. <bold>(C)</bold> Outlier-level significance [-log10(p), y-axis] vs. effect size (junction count/total junction count-mean (total junctions count/total count of junctions in the cluster), x-axis) for the patient. There are 2030s outliers with an adjusted <italic>p</italic> &#x0003C; 0.05 in 1442 genes (red dots indicating two clusters in <italic>SCP2</italic>, vertical dotted lines indicating the effect size cutoff). <bold>(D)</bold> Sashimi plot of the eighth exon-skipping event (indicated in black arrow) in RNA-seq samples of the <italic>SCP2</italic>-affected (red) and three representative <italic>SCP2</italic>-unaffected (orange) individuals. The RNA-seq read coverage is given as the log10 RPKM-value (Reads Per Kilobase of transcript per Million mapped reads, y-axis), and the number of splits reads spanning an intron is indicated on the exon-connecting line. <bold>(E)</bold> The skipping event is observable in the RT-PCR product from patient blood. Mt: mtant type, wt: wide type. <bold>(F)</bold> Exon 8 skipping is validated by the Sanger sequencing of RT-PCR product. <bold>(G)</bold> schematic representation of the SCPx and the affected domain of the index patient, surrounding the amino acids region coding by the eighth exon (p. 225&#x02013;254, indicated between the red cross). <bold>(H)</bold> Protein sequence alignment of <italic>SCP2</italic> orthologs, showing the region surrounding the p. 225&#x02013;254 is relatively conserved (indicated between the red dot lines). <sup>&#x0002A;</sup>Indicates the termination codon.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fneur-14-1270793-g0002.tif"/>
</fig>
<p>The patient&#x00027;s seizures were effectively halted with diazepam, and the psychiatric symptoms gradually improved. Subsequently, the patient was discharged while being placed on a phytanic acid-restricted diet.</p></sec>
<sec sec-type="discussion" id="s3">
<title>Discussion</title>
<p>SCPx deficiency, a rare autosomal recessive monogenic metabolic encephalopathy, has been reported in only two patients. One patient presented with leukoencephalopathy with clinical features such as slowly progressive dystonia, stutter, and motor neuropathy (<xref ref-type="bibr" rid="B2">2</xref>). The other patient developed hand clumsiness in his 30s, followed by gait disturbance and deafness (<xref ref-type="bibr" rid="B3">3</xref>). The index patient displayed episodic psychobehavioral disturbances, stutter, tremors, and epilepsy. MRI findings were consistent among all three patients, revealing symmetrical thalamus and brainstem lesions without gadolinium enhancement. As summarized in <xref ref-type="table" rid="T1">Table 1</xref>, these shared clinical features in SCPx deficiency include stutter, tremors, and symmetrical lesions in the thalamus and brainstem without gadolinium enhancement (see <xref ref-type="table" rid="T1">Table 1</xref>). Importantly, our patient first presented with episodic psychosis and epilepsy in SCPx deficiency patients highlighting the necessity for clinicians to consider the <italic>SCP2</italic> variant during the etiological examination of individuals presenting with episodic psychosis and epilepsy.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Clinical phenotypes and laboratory investigation results of patients with <italic>SCP2</italic> mutations.</p></caption>
<table frame="box" rules="all">
<thead>
<tr style="background-color:#919497;color:#ffffff">
<th valign="top" align="left"><bold>Patient ID</bold></th>
<th valign="top" align="left"><bold>Patient 1<sup>2</sup></bold></th>
<th valign="top" align="left"><bold>Patient 2<sup>3</sup></bold></th>
<th valign="top" align="left"><bold>Index Patient</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Gender</td>
<td valign="top" align="left">Male</td>
<td valign="top" align="left">Male</td>
<td valign="top" align="left">Male</td>
</tr> <tr>
<td valign="top" align="left">Age at disease onset</td>
<td valign="top" align="left">7 years</td>
<td valign="top" align="left">30 years</td>
<td valign="top" align="left">Young, not clear</td>
</tr> <tr>
<td valign="top" align="left">Clinical neurology symptoms</td>
<td valign="top" align="left">torticollis, tremor, nystagmus, hyposmia</td>
<td valign="top" align="left">hand clumsiness, gait disturbance, deafness</td>
<td valign="top" align="left">episodic psychobehavioral disturbances, stutter, tremor, epilepsy</td>
</tr> <tr>
<td valign="top" align="left">Neurological examination</td>
<td valign="top" align="left">hyposmia, pathological saccadic eye movements, brisk deep-tendon reflexes of the upper extremities but diminished reflexes of the lower extremities, plantar sole responses, and a reduced vibration sense of 4/8 at the lateral malleoli</td>
<td valign="top" align="left">slow ocular saccades, muscle tone was increased with brisk deep tendon reflexes throughout, proprioception was impaired, mild dysmetria, dysdiadochokinesis, and a wide-based gait</td>
<td valign="top" align="left">Inaccurate orientation, slightly slow response, talking nonsense, and involuntary shaking of lips and upper limbs, positive right ankle clonus, double metacarpophalangeal reflex and sucking reflex positive, bilateral Babinski sign and allelic sign positive.</td>
</tr> <tr>
<td valign="top" align="left">Cranial MRI results</td>
<td valign="top" align="left">bilateral hyperintense T2 signals in the thalamus, butterfly-like lesions in the pons, and lesions in the occipital region, without gadolinium enhancement</td>
<td valign="top" align="left">abnormal T2 signal, in the pons and thalamus</td>
<td valign="top" align="left">bilateral hyperintense T2 signals in the thalamus, and butterfly-like lesions in the pons</td>
</tr> <tr>
<td valign="top" align="left">Electrophysiology</td>
<td valign="top" align="left">a predominantly motor and slight sensory neuropathy, with conduction blocks in the tibial nerves, reduced motor action potentials in the left peroneal nerve, and reduced amplitude of the left sural nerve</td>
<td valign="top" align="left">No evidence of polyneuropathy</td>
<td valign="top" align="left">No evidence of polyneuropathy</td>
</tr> <tr>
<td valign="top" align="left">Pristanic acid</td>
<td valign="top" align="left">39.8 &#x003BC;mol/ L, control range 0&#x02013;3.1</td>
<td valign="top" align="left">34.1 &#x003BC;mol/L, normal range 0&#x02013;1.5</td>
<td valign="top" align="left">0.96 &#x003BC;mol/L, control range &#x0003C; 0.6</td>
</tr> <tr>
<td valign="top" align="left">Phytanic acid</td>
<td valign="top" align="left">10.1 &#x003BC;mol/L, control range 0&#x02013;9</td>
<td valign="top" align="left">13.8 &#x003BC;mol/L, normal &#x0003C; 11.5</td>
<td valign="top" align="left">0.74 &#x003BC;mol/L, control range &#x0003C; 5.7</td>
</tr> <tr>
<td valign="top" align="left">Genetics</td>
<td valign="top" align="left">c.545_546insA(hom);</td>
<td valign="top" align="left">c.121G&#x0003E;T &#x00026;c.349C&#x0003E;T(comhet);</td>
<td valign="top" align="left">c.674 &#x0002B; 1g&#x0003E;c(hom);</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">p.I184fs<sup>&#x0002A;</sup>7</td>
<td valign="top" align="left">p.Glu41<sup>&#x0002A;</sup>&#x00026;p.Gln117<sup>&#x0002A;</sup></td>
<td valign="top" align="left">27 amino acids deleted</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Patients 1 and 2 described in the references (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>), and index patient described in the study. (<sup>&#x0002A;</sup> Indicates the termination codon).</p>
</table-wrap-foot>
</table-wrap>
<p>Patients in the literature exhibited elevated pristanic acid levels, whereas the index patient showed a mild increase. Mutations in <italic>HSD17B4</italic>, which resulted in less structural damage to the D-bifunctional protein, were associated with a milder clinical and biochemical presentation (<xref ref-type="bibr" rid="B4">4</xref>). The D-bifunctional protein is situated upstream of SCPx in peroxisomal beta-oxidation. In our patient, the deletion of amino acid residues due to exon skipping occurs within a relatively conserved region of the protein, and this deletion region intersects with the thiolase_N domain (see <xref ref-type="fig" rid="F2">Figures 2G</xref>, <xref ref-type="fig" rid="F2">H</xref>). The function of the thiolase may be impaired but remains partially functional.</p>
<p>Intriguingly, episodic psychosis in the index patient typically follows infections, indicating that &#x0201C;crises&#x0201D; in SCPx deficiency may be provoked by factors such as infections or extended fasting, similar to certain metabolic encephalopathies, such as isolated methylmalonic acidemia (<xref ref-type="bibr" rid="B5">5</xref>).</p></sec>
<sec sec-type="data-availability" id="s4">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p></sec>
<sec sec-type="ethics-statement" id="s5">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Second Xiangya Hospital, Central South University (Changsha, China). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></sec>
<sec sec-type="author-contributions" id="s6">
<title>Author contributions</title>
<p>HT: Formal analysis, Writing&#x02014;original draft. YL: Software, Writing&#x02014;review and editing. ZT: Data curation, Writing&#x02014;review and editing. JT: Investigation, Writing&#x02014;review and editing. JF: Investigation, Supervision, Writing&#x02014;original draft.</p></sec>
</body>
<back>
<sec sec-type="funding-information" id="s7">
<title>Funding</title>
<p>This research was supported by the Natural Science Foundation of Hunan (Grant/Award Number: 2023JJ30750) and the National Natural Science Foundation Youth Fund Project (Grant/Award Number: 82201354).</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname> <given-names>R</given-names></name> <name><surname>Kallen</surname> <given-names>CB</given-names></name> <name><surname>Babalola</surname> <given-names>GO</given-names></name> <name><surname>Rennert</surname> <given-names>H</given-names></name> <name><surname>Billheimer</surname> <given-names>JT</given-names></name> <name><surname>Strauss</surname> <given-names>JF</given-names></name></person-group>. <article-title>3rd. Cloning and expression of a cDNA encoding human sterol carrier protein 2</article-title>. <source>Proc Natl Acad Sci U S A.</source> (<year>1991</year>) <volume>88</volume>:<fpage>463</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.88.2.463</pub-id><pub-id pub-id-type="pmid">1703300</pub-id></citation></ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferdinandusse</surname> <given-names>S</given-names></name> <name><surname>Kostopoulos</surname> <given-names>P</given-names></name> <name><surname>Denis</surname> <given-names>S</given-names></name> <name><surname>Rusch</surname> <given-names>H</given-names></name> <name><surname>Overmars</surname> <given-names>H</given-names></name> <name><surname>Dillmann</surname> <given-names>U</given-names></name> <etal/></person-group>. <article-title>Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukencephalopathy with dystonia and motor neuropathy</article-title>. <source>Am J Hum Genet.</source> (<year>2006</year>) <volume>78</volume>:<fpage>1046</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1086/503921</pub-id><pub-id pub-id-type="pmid">16685654</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname> <given-names>R</given-names></name> <name><surname>Lewis-Smith</surname> <given-names>D</given-names></name> <name><surname>Douroudis</surname> <given-names>K</given-names></name> <name><surname>Duff</surname> <given-names>J</given-names></name> <name><surname>Keogh</surname> <given-names>M</given-names></name> <name><surname>Pyle</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>SCP2 mutations and neurodegeneration with brain iron accumulation</article-title>. <source>Neurology.</source> (<year>2015</year>) <volume>85</volume>:<fpage>1909</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000002157</pub-id><pub-id pub-id-type="pmid">26497993</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferdinandusse</surname> <given-names>S</given-names></name> <name><surname>Ylianttila</surname> <given-names>MS</given-names></name> <name><surname>Gloerich</surname> <given-names>J</given-names></name> <name><surname>Koski</surname> <given-names>MK</given-names></name> <name><surname>Oostheim</surname> <given-names>W</given-names></name> <name><surname>Waterham</surname> <given-names>HR</given-names></name> <etal/></person-group>. <article-title>Mutational spectrum of D-bifunctional protein deficiency and structure-based genotype-phenotype analysis</article-title>. <source>Am J Hum Genet.</source> (<year>2006</year>) <volume>78</volume>:<fpage>112</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1086/498880</pub-id><pub-id pub-id-type="pmid">16385454</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forny</surname> <given-names>P</given-names></name> <name><surname>Horster</surname> <given-names>F</given-names></name> <name><surname>Ballhausen</surname> <given-names>D</given-names></name> <name><surname>Chakrapani</surname> <given-names>A</given-names></name> <name><surname>Chapman</surname> <given-names>KA</given-names></name> <name><surname>Dionisi-Vici</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision</article-title>. <source>J Inherit Metab Dis.</source> (<year>2021</year>) <volume>44</volume>:<fpage>566</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1002/jimd.12370</pub-id><pub-id pub-id-type="pmid">33595124</pub-id></citation></ref>
</ref-list> 
</back>
</article> 